Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ASND Ascendis Pharma A/S

Post-Mkt 01-15 16:16:25 EST

215.04

-2.28

-1.05%

盘后215.04

+0.000.00%

16:14 EST

High219.00	Low213.49	Vol303.28K
Open217.32	D1 Closing217.32	Amplitude2.54%
Mkt Cap13.27B	Tradable Cap12.92B	Total Shares61.70M
T/O65.50M	T/O Rate0.50%	Tradable Shares60.08M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ASND","market":"US","secType":"STK","nameCN":"Ascendis Pharma A/S","latestPrice":215.04,"timestamp":1768510800000,"preClose":217.32,"halted":0,"volume":303278,"hourTrading":{"tag":"盘后","latestPrice":215.04,"preClose":215.04,"latestTime":"16:14 EST","volume":7007,"amount":1506785.28,"timestamp":1768511657614},"delay":0,"floatShares":60083367,"shares":61695200,"eps":-4.538371,"marketStatus":"Post-Mkt","change":-2.28,"latestTime":"01-15 16:16:25 EST","open":217.32,"high":219,"low":213.49,"amount":65501676.68271,"amplitude":0.025354,"askPrice":219.23,"askSize":9,"bidPrice":210.89,"bidSize":9,"shortable":3,"etf":0,"ttmEps":-4.538371,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1768525200000},"marketStatusCode":4,"adr":1,"adrRate":1,"listingDate":1422421200000,"exchange":"NASDAQ","adjPreClose":217.32,"postHourTrading":{"tag":"盘后","latestPrice":215.04,"preClose":215.04,"latestTime":"16:14 EST","volume":7007,"amount":1506785.28,"timestamp":1768511657614},"volumeRatio":0.345026,"impliedVol":0.5552,"impliedVolPercentile":0.7769},"requestUrl":"/m/hq/s/ASND/wiki","defaultTab":"wiki","newsList":[{"id":"2602517314","title":"Ascendis Pharma price target raised to $246 from $242 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2602517314","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602517314?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:37","pubTimestamp":1768221474,"startTime":"0","endTime":"0","summary":"BofA raised the firm’s price target on Ascendis Pharma (ASND) to $246 from $242 and keeps a Buy rating on the shares after the company announced pr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-price-target-raised-to-246-from-242-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-price-target-raised-to-246-from-242-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0320765992.SGD","LU0109394709.USD","ASND","LU0889565916.HKD","BK4585"],"gpt_icon":0},{"id":"2602022503","title":"Ascendis Pharma Plans $120 Million Share Repurchase Program In 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602022503","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602022503?lang=en_us&edition=fundamental","pubTime":"2026-01-10 07:23","pubTimestamp":1768000995,"startTime":"0","endTime":"0","summary":"Jan 9 (Reuters) - Ascendis Pharma A/S ::*ASCENDIS PHARMA PROVIDES BUSINESS AND STRATEGIC ROADMAP UPDATE AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE*PLANS $120 MILLION SHARE REPURCHASE PROGRAM IN ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nRSD9z57BR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","BK4135","LU0648001328.SGD","LU1699723380.USD","LU0130517989.USD","LU0980610538.SGD","BK4585","BK4139","LU0130102774.USD","LU0320765992.SGD","LU1201861249.SGD","LU1571399168.USD","BK4588","BK","LU0477156953.USD","ASND","LU0889565916.HKD","BK4559"],"gpt_icon":0},{"id":"2602430246","title":"Ascendis Pharma A/S outlines strategy to expand rare disease portfolio and target blockbuster revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2602430246","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602430246?lang=en_us&edition=fundamental","pubTime":"2026-01-10 07:18","pubTimestamp":1768000707,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S presented updates on its business and product portfolio at the 44th Annual J.P. Morgan Healthcare Conference. The company reported preliminary product revenue of approximately 240 million for the fourth quarter of 2025 and around 683 million for the full year 2025. Its endocrinology rare disease medicines include YORVIPATH for adult hypoparathyroidism, SKYTROFA for pediatric and adult growth hormone deficiency, and TransCon CNP, which is under FDA review with a PDUFA date of February 28, 2026. Ascendis Pharma is expanding commercial launches for its products across more than 30 countries and plans further expansion by the end of 2026. The company is also advancing its TransCon technology platform and pursuing additional opportunities in areas such as ophthalmology, obesity, metabolic diseases, and oncology. Ascendis targets blockbuster status for multiple products and aims to achieve over 5 billion in annual revenue by 2030. You can access the full presentation thro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDLb2z5Ty:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0130102774.USD","LU0980610538.SGD","LU1571399168.USD","BK","LU1699723380.USD","ASND","BK4135","LU0130517989.USD","LU0648001328.SGD","BK4559","LU0109394709.USD","LU0889565916.HKD","LU1201861249.SGD","LU0320765992.SGD","BK4139","LU0477156953.USD","BK4585","BK4588"],"gpt_icon":0},{"id":"2602029233","title":"Ascendis Pharma Announces 2026 Strategic Roadmap Including Global Commercial Expansion, Anticipated Third TransCon Product Approval, Advancing R&D Pipeline, and $120 Million Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2602029233","media":"Reuters","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602029233?lang=en_us&edition=fundamental","pubTime":"2026-01-10 07:01","pubTimestamp":1767999709,"startTime":"0","endTime":"0","summary":"Ascendis Pharma Announces 2026 Strategic Roadmap Including Global Commercial Expansion, Anticipated Third TransCon Product Approval, Advancing R&D Pipeline, and $120 Million Share Repurchase Program. Ascendis Pharma A/S has outlined its strategic roadmap for 2026, focusing on expanding its global biopharma presence. Key future plans include accelerating global penetration and commercial expansion, anticipating a potential third TransCon product approval with blockbuster potential, and advancing a pipeline of differentiated TransCon product candidates. The company expects continued growth driven by its TransCon technology platform, R&D capabilities, and maturing commercial infrastructure. Financial initiatives include a planned $120 million share repurchase program, with flexibility in execution based on market conditions. Ascendis Pharma’s leadership emphasized these goals during a presentation at the 44th Annual J.P. Morgan Healthcare Conference.Disclaimer: This news brief was created","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL4NfpLn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU0130102774.USD","NDAQ","IE00B3QW5Z07.USD","SG9999014039.USD","LU0109394709.USD","IE00BGHQF748.EUR","BK4559","ASND","LU0648001328.SGD","SG9999014021.USD","LU0889565916.HKD","BK4139","LU1699723380.USD","LU2210149790.SGD","LU2095319765.USD","LU0314104364.USD","LU0320765992.SGD","BK4112","BK","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014005.SGD","LU0980610538.SGD","LU2210150020.SGD","LU1201861249.SGD","LU0130517989.USD","BK4135","BK4585","LU0477156953.USD","BK4588","LU1571399168.USD"],"gpt_icon":0},{"id":"2602308381","title":"Wedbush Raises Ascendis Pharma Price Target to $240 From $220, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2602308381","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602308381?lang=en_us&edition=fundamental","pubTime":"2026-01-10 00:46","pubTimestamp":1767977216,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (ASND) has an average rating of buy and mean price target of $258.82, according to analysts polled by FactSet.Price: 210.52, Change: +1.77, Percent Change: +0.85","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LU0889565916.HKD","ASND","LU0320765992.SGD","LU0109394709.USD","BK4585"],"gpt_icon":0},{"id":"2602378318","title":"Ascendis Pharma a/S : Wells Fargo Raises Target Price to $322 From $297","url":"https://stock-news.laohu8.com/highlight/detail?id=2602378318","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602378318?lang=en_us&edition=fundamental","pubTime":"2026-01-09 19:57","pubTimestamp":1767959864,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nFWN3YA120:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","BK4585","BK4139","ASND","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0},{"id":"2602184933","title":"Ascendis Pharma A/S Releases Data on TransCon CNP and TransCon hGH Combination Therapy in Achondroplasia","url":"https://stock-news.laohu8.com/highlight/detail?id=2602184933","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602184933?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:17","pubTimestamp":1767907022,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S has published a document on the clinical results for combination therapy with TransCon CNP and TransCon hGH in children with achondroplasia. The document provides data on annualized growth velocity, height Z-score changes, body proportionality, and safety outcomes, including adverse events. The results include information on efficacy and tolerability observed over 52 weeks of treatment. The full document can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief on January 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL6027W7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","ASND","LU1571399168.USD","LU0477156953.USD","LU1201861249.SGD","BK","LU0980610538.SGD","BK4139","BK4585","BK4559","LU0889565916.HKD","BK4588","LU0130102774.USD","LU0130517989.USD","LU0320765992.SGD","LU1699723380.USD","BK4135","LU0648001328.SGD"],"gpt_icon":0},{"id":"2602318785","title":"Ascendis Pharma announces topline results from Week 52 of COACH trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2602318785","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602318785?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:11","pubTimestamp":1767906661,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (ASND) announced topline results from Week 52 of COACH, the first Phase 2 clinical trial to evaluate combination therapy with once-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-announces-topline-results-from-week-52-of-coach-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-announces-topline-results-from-week-52-of-coach-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","BK4585","BK4139","ASND"],"gpt_icon":0},{"id":"2602331838","title":"Ascendis Pharma Reports Positive 52-Week Results from COACH Trial in Pediatric Achondroplasia","url":"https://stock-news.laohu8.com/highlight/detail?id=2602331838","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602331838?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:01","pubTimestamp":1767906078,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S announced topline results from Week 52 of the COACH Phase 2 clinical trial, evaluating combination therapy with once-weekly TransCon CNP  and once-weekly TransCon hGH  in children with achondroplasia. The combination therapy demonstrated durable growth, improvements in body proportionality and arm span, and was generally well tolerated with mild treatment-emergent adverse events. The annualized growth velocity exceeded the 97th percentile of average stature children, and height Z-score improvements indicated a tripling of efficacy compared to TransCon CNP monotherapy. All participants completed 52 weeks of treatment and remain on therapy. The Week 52 results have been presented and a slide presentation is available on the Ascendis Pharma website. Ascendis Pharma has submitted a protocol and held an end of Phase 2 meeting with the FDA regarding a Phase 3 trial of TransCon CNP and TransCon hGH in pediatric achondroplasia.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL5JZ0WL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0130102774.USD","NDAQ","LU1571399168.USD","BK","SG9999014021.USD","BK4112","LU0889565916.HKD","IE00BKPKM429.USD","LU0648001328.SGD","ASND","LU1699723380.USD","BK4559","LU2210150020.SGD","BK4139","LU0477156953.USD","LU1201861249.SGD","LU2210149790.SGD","LU0109394709.USD","LU0320765992.SGD","LU2095319765.USD","LU0980610538.SGD","SG9999014039.USD","SG9999014005.SGD","BK4588","IE00B3QW5Z07.USD","BK4585","BK4135","IE00B64PRP62.GBP","LU0130517989.USD","SG9999014013.SGD","IE00BGHQF748.EUR","LU0314104364.USD"],"gpt_icon":0},{"id":"2601369344","title":"RBC Raises Price Target on Ascendis Pharma to $245 From $240, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369344","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369344?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:12","pubTimestamp":1767874353,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (ASND) has an average rating of buy and mean price target of $258.82, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","BK4139","ASND","BK4585"],"gpt_icon":0},{"id":"2594367297","title":"European Equities Traded in the US as American Depositary Receipts Little Changed in Friday Trading; Gains 2% for Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2594367297","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594367297?lang=en_us&edition=fundamental","pubTime":"2025-12-27 00:07","pubTimestamp":1766765233,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were little changed late Friday morning, edging 0.07% higher to 1,689.69 on the S&P Europe Select ADR Index, which has risen 2% for t","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BHP.AU","BK7095","BDRX","CLLS","BK4158","BK4077","BK4585","GRFS","SNN","BK4142","NTZ","BK4168","LU2462157665.USD","BK4139","ASND","BK4082","EVAX","BK4117","LU0300736492.USD","BUD.AU","LU2456880835.USD","LU0109394709.USD","LU1829250122.USD","AFG","TRVG","BUD","BK4095","AZN","EDAP","BK7119","CUK","BK4007","LU0320765992.SGD","LU0300736062.USD","BK4107","BK4568","LU2417539215.USD","BK4588","BK7507","LU0889565916.HKD","AMRN","NCNA","BCYC","BHP","BK7511","LU2236285917.USD"],"gpt_icon":0},{"id":"2592888661","title":"European Equities Traded in the US as American Depositary Receipts Track Higher in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2592888661","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592888661?lang=en_us&edition=fundamental","pubTime":"2025-12-19 00:05","pubTimestamp":1766073950,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking higher late Thursday morning, rising 0.63% to 1,651.45 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by 3D printer company Materialise  and accommodations booking site trivago , which rose 5.6% and 4.8%, respectively. They were followed by biopharmaceutical company Cellectis  and semiconductor company Sequans Communications , which increased 3.9% and 2%, respectively.The decliners from continental Europe were led by biopharmaceutical company DBV Technologies  and furniture manufacturer Natuzzi , which dropped 6.6% and 5%, respectively. They were followed by biopharmaceutical company argenx  and pharmaceutical company Ascendis Pharma , which lost 1.4% and 1.1%, respectively.From the UK and Ireland, the gainers were led by biotech firm Trinity Biotech  and biopharmaceutical company Mereo BioPharma Group , which advanced 4.1% and 2.9%, respectively. They were followed by bio","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1162221912.USD","BP","BK4207","BK4521","BK4201","BK4546","BK4139","IE0002141913.USD","ARGX","BK4007","BK4095","BK4588","MTLS","BK4505","IE00BFTCPJ56.SGD","LU0162691827.USD","AMRN","DBVT","BK4077","LU1983260115.SGD","BCYC","IE00BJT1NW94.SGD","TRIB","IE0009355771.USD","BDRX","ASND","BK4082","IE0034235188.USD","LU0889565916.HKD","LU0109394709.USD","BCS","LU1829250122.USD","BK4023","AKTX","SQNS","IE00BJJMRZ35.SGD","CLLS","BK4585","LU2324357040.USD","LU0320765646.SGD","LU0072461881.USD","AFG","NTZ","MREO","BK4107","LU0320765992.SGD","IE00B4R5TH58.HKD","TRVG","IE00B2B36J28.USD","BK4141"],"gpt_icon":0},{"id":"2591830688","title":"European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2591830688","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591830688?lang=en_us&edition=fundamental","pubTime":"2025-12-13 00:17","pubTimestamp":1765556266,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were trending lower late Friday morning, falling 1% to 1,646.41 on the S&P Europe Select ADR Index, which is up 1.3% so far this week","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NOK","LU0006061336.USD","ASND","BK4075","BK4207","AKTX","BDRX","BK4547","IE00BKVL7J92.USD","BK4142","LU1093756325.SGD","IE00BZ1G4Q59.USD","BK4020","AUTL","DAVA.AU","LU0320765992.SGD","BK4521","BK4139","AFG","BTI","IHG","DAVA","LU0889565916.HKD","BK7062","BK7104","TEF","DBVT","EQNR","BK4082","BK4162","BK4532","LU2543165471.USD","PUK","LU0154236417.USD","LU0109394709.USD","IE00BMPRXN33.USD","CLLS","BK4117","BK4588","BK4115","BTI.AU","EDAP","LYG","NVO.AU","LU0648005311.SGD","LU0084288595.USD","BK4107","BK4134","LU1093756168.USD"],"gpt_icon":1},{"id":"2590349420","title":"Monolithic Power, Ascendis Pharma And More: CNBC's 'Final Trades'","url":"https://stock-news.laohu8.com/highlight/detail?id=2590349420","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590349420?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:16","pubTimestamp":1765286160,"startTime":"0","endTime":"0","summary":"Amy Raskin, CIO at Chevy Chase Trust, named Ascendis Pharma (ASND) as her final trade on CNBC's Halftime Report. FDA extended review for TransCon CNP.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/09/Analyst.jpeg?optimize=medium&dpr=2&auto=webp&width=120","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/09/Analyst.jpeg?optimize=medium&dpr=2&auto=webp&width=120"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/long-ideas/25/12/49277738/monolithic-power-ascendis-pharma-and-more-cnbcs-final-trades","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/long-ideas/25/12/49277738/monolithic-power-ascendis-pharma-and-more-cnbcs-final-trades","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0353189763.USD","IE00BN0W2V16.EUR","LU0274383776.USD","LU1267930730.SGD","LU2087625088.SGD","LU2272731782.SGD","BK4585","IE00BD6J9T35.USD","LU2089985449.USD","LU0320765059.SGD","LU1852331112.SGD","LU0353189680.USD","LU0109394709.USD","LU0708995401.HKD","LU2322448791.USD","LU0672654240.SGD","LU2473716301.USD","LU0081259029.USD","LU2272731865.HKD","LU2360107168.USD","LU1992135399.USD","IE00BN0W2T93.GBP","BK4588","LU2272731600.USD","LU2322448957.HKD","LU1992135472.HKD","LU1861215975.USD","LU2290526834.HKD","MPWR","IE00BN0W2W23.USD","ASND","LU0109391861.USD","BK4139","LU0320765992.SGD","LU2360106780.USD","LU0889565916.HKD","LU2250418816.HKD","LU0056508442.USD","LU2931357623.SGD","LU1861220033.SGD","BK4141"],"gpt_icon":0},{"id":"2589497398","title":"Biotech Is Healthier Than Investors Think -- Barron's","url":"https://stock-news.laohu8.com/highlight/detail?id=2589497398","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589497398?lang=en_us&edition=fundamental","pubTime":"2025-12-06 10:30","pubTimestamp":1764988200,"startTime":"0","endTime":"0","summary":"If you look at a stock chart mapping the performance of the State Street SPDR S&P Biotech exchange-traded fund since early 2021, it seems to tell a simple story: The biotech sector has been a disaster for investors.The ETF, which trades under the ticker XBI, collapsed in February 2021 as the early-pandemic-era enthusiasm for biotech dissipated like air from a popping balloon. It was more or less moribund until this past summer, when biotech stocks began to rebound, apparently driven by an easing of investor worries over the Trump administration's efforts to reduce drug prices and a marketwide shift toward riskier sectors.RA Capital, which Kolchinsky co-founded in 2004, started as a biotech-focused hedge fund. It has since expanded its focus and now invests in private biotechs and even forms start-ups of its own. It calls itself a multistage investment manager and says it had $13.3 billion under management as of the end of October.Some were getting acquired, and some were launching thei","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1929549753.HKD","BK4211","LU0070302665.USD","LU1917777945.USD","LU1066053197.SGD","LU1941712348.USD","IE00B2B36J28.USD","IE00BSNM7G36.USD","LU1116320737.USD","LU1989771016.USD","LU2324357040.USD","LU0006306889.USD","XBI","BK4585","IE00BFTCPJ56.SGD","SG9999002232.USD","IE0002141913.USD","LU1037948541.HKD","SG9999015358.SGD","LU1093756325.SGD","LU0265550946.USD","BK4007","SG9999015341.SGD","LU0965508806.USD","SG9999013999.USD","SG9999002224.SGD","IE00BLSP4239.USD","LU0211331839.USD","LU2112291526.USD","BK4581","LU0965509010.AUD","IE00B1BXHZ80.USD","LU1069347547.HKD","IE00B4R5TH58.HKD","SG9999014567.USD","LU0889565916.HKD","SG9999001176.USD","SG9999014559.SGD","LU2023250843.SGD","BK4534","LU0098860793.USD","LU0203345920.USD","LU1934455194.USD","BK4559","BK4588","LU2461242641.AUD","LU2361044865.SGD","LU0203347892.USD","LU1066051225.USD","LU0208291251.USD","LU1037948897.HKD","LU1934455863.HKD","LU1023059063.AUD","SG9999001176.SGD","SG9999001440.SGD","LU2468319806.SGD","LU0238689110.USD","LU0265550359.USD","LU1430594728.SGD","LU1061106388.HKD","LU0861579265.USD","LU1057294990.SGD","LU2106854487.HKD","LU1941712264.USD","IE00BBT3K403.USD","LU1116320901.HKD","LU1162221912.USD","IE00BLSP4452.SGD","IE00BN8TJ469.HKD","LU1983299246.USD","LU0965509283.SGD","LU1989772923.USD","LU1035773651.USD","LU0985320562.USD","LU0320765646.SGD","SGXZ57979304.SGD","LU0058720904.USD","LU1699723380.USD","LU0289739699.SGD","BK4516","LU1066051498.USD","LU0266013472.USD","LU1585245621.USD","LU1093756168.USD","ASND","LU1974910355.USD","BK4139","LU1291159041.SGD","LU0320765992.SGD","IE000M9KFDE8.USD","LU1066051811.HKD","LU1989772840.SGD","LU2361044949.HKD","SG9999014575.USD","BK4533","BK4550","LU2361045086.USD","LU1934455277.USD","LU1571399168.USD","LU0109394709.USD","LU2089984988.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU2023250504.SGD","SG9999014542.SGD","LU0320765489.SGD","LU0965509101.SGD","LU0122379950.USD","LU0106261372.USD","LU0234572021.USD","IE0009355771.USD"],"gpt_icon":0},{"id":"2589273835","title":"The Biotech Industry Is Healthier Than Investors Think. These Are the Stocks to Watch. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2589273835","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589273835?lang=en_us&edition=fundamental","pubTime":"2025-12-05 00:10","pubTimestamp":1764864600,"startTime":"0","endTime":"0","summary":"If you look at a stock chart mapping the performance of the State Street SPDR S&P Biotech exchange-traded fund since early 2021, it seems to tell a simple story: The biotech sector has been a disaster for investors.The ETF, which trades under the ticker XBI, collapsed in February 2021 as the early-pandemic-era enthusiasm for biotech dissipated like air from a popping balloon. It was more or less moribund until this past summer, when biotech stocks began to rebound, apparently driven by an easing of investor worries over the Trump administration's efforts to reduce drug prices and a marketwide shift toward riskier sectors.RA Capital, which Kolchinsky co-founded in 2004, started as a biotech-focused hedge fund. It has since expanded its focus and now invests in private biotechs and even forms start-ups of its own. It calls itself a multistage investment manager and says it had $13.3 billion under management as of the end of October.Some were getting acquired, and some were launching thei","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BFTCPJ56.SGD","LU1989772923.USD","LU1941712264.USD","SG9999014559.SGD","IE00BN8TJ469.HKD","SG9999014567.USD","LU1162221912.USD","IE0002141913.USD","RYTM","LU1989772840.SGD","IE00BJJMRZ35.SGD","IE00BBT3K403.USD","BK4516","LU2023250504.SGD","LU1585245621.USD","LU1061106388.HKD","BK4588","LU1066051225.USD","LU0238689110.USD","IE00B2B36J28.USD","MRK","LU1934455277.USD","XBI","LU2023250843.SGD","SG9999015341.SGD","CDTX","LU0266013472.USD","LU2106854487.HKD","LU0211331839.USD","LU1934455863.HKD","LU1571399168.USD","LU2361045086.USD","LU1037948541.HKD","ISBC","LU2461242641.AUD","LU1291159041.SGD","LU1066053197.SGD","ASND","SG9999015358.SGD","LU1093756168.USD","LU0861579265.USD","LU1430594728.SGD","LU2468319806.SGD","LU0320765992.SGD","LU1983299246.USD","LU1057294990.SGD","LU2112291526.USD","LU0070302665.USD","IE00B1BXHZ80.USD"],"gpt_icon":0},{"id":"2586368147","title":"Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2586368147","media":"Benzinga","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586368147?lang=en_us&edition=fundamental","pubTime":"2025-11-28 23:13","pubTimestamp":1764342780,"startTime":"0","endTime":"0","summary":"FDA extends Ascendis' TransCon CNP review to Feb. 28, 2026, after new data submission related to post-marketing study requirements.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/28/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/28/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/fda/25/11/49115519/ascendis-pharma-hit-by-fda-delay-as-transcon-cnp-decision-slips-to-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/25/11/49115519/ascendis-pharma-hit-by-fda-delay-as-transcon-cnp-decision-slips-to-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU0889565916.HKD","IE00BD4GTV84.USD","BK4208","BK4139","IE00BD4GTW91.USD","BK4585","CNP","BK4588","LU2380233275.USD","IE00BD4GTT62.SGD","LU0320765992.SGD","ASND","LU0109394709.USD"],"gpt_icon":0},{"id":"2586266977","title":"European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2586266977","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586266977?lang=en_us&edition=fundamental","pubTime":"2025-11-27 00:03","pubTimestamp":1764172980,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were surging higher late Wednesday morning, rising 1.25% to 1,614.11 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by pharmaceutical companies Novo Nordisk  and Ascendis Pharma , which rose 3.5% and 1.8%, respectively. They were followed by biopharmaceutical company DBV Technologies  and lender Banco Santander , which were up 1.7% and 1.6%, respectively.The decliners from continental Europe were led by biopharmaceutical company Cellectis  and brewing company Anheuser-Busch InBev , which fell 4.6% and 1%, respectively. They were followed by biotech firm Evaxion  and pharmaceutical company Sanofi , which were off 0.9% each.From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics  and NuCana , which increased 5.5% and 3.7%, respectively. They were followed by lenders Barclays  and Lloyds Banking Group , which advanced 3.2% each.The decliners from the","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DGE.UK","AKTX","IE00BKVL7J92.USD","LU0154236417.USD","SNY","SAN","MREO","BK7119","BK4139","BCS","AUTL","NVO.AU","CLLS","BK4599","NCNA","ASND","BK7142","BK4117","BK4169","LYG","BK4107","BK4521","EVAX","DBVT","NVO","BK4532","LU1093756325.SGD","BK4158","BK4207","BK4588","BUD","IE00BFXG1179.USD","BK4007","BK7104","LU0109394709.USD","BK4505","BCYC","DEO","SAN.AU","BK4559","IE00BZ1G4Q59.USD","LU0320765992.SGD","LU0889565916.HKD","AFG","BUD.AU","LU1093756168.USD","BK4585"],"gpt_icon":1},{"id":"2586251597","title":"Stifel Nicolaus Remains a Buy on Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2586251597","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586251597?lang=en_us&edition=fundamental","pubTime":"2025-11-26 19:57","pubTimestamp":1764158265,"startTime":"0","endTime":"0","summary":"In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Ascendis Pharma, with a price target of $254.00. Thom...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-ascendis-pharma-asnd-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-ascendis-pharma-asnd-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","LU0889565916.HKD","CFA","LU0109394709.USD","BK4127","SF","BK4585","BK4139","ASND"],"gpt_icon":0},{"id":"2586251599","title":"Ascendis Pharma (ASND) Receives a Buy from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2586251599","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586251599?lang=en_us&edition=fundamental","pubTime":"2025-11-26 19:57","pubTimestamp":1764158257,"startTime":"0","endTime":"0","summary":"In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on Ascendis Pharma, with a price target of $297.00. Archila cove...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ascendis-pharma-asnd-receives-a-buy-from-wells-fargo-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ascendis-pharma-asnd-receives-a-buy-from-wells-fargo-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0052756011.USD","BK4501","LU0267386448.USD","LU1280957306.USD","LU0162691827.USD","LU2361044865.SGD","LU0971096721.USD","LU1668664300.SGD","LU0289960550.SGD","IE000M9KFDE8.USD","LU0208291251.USD","LU0314106906.USD","LU0211328371.USD","IE00B7SZLL34.SGD","LU0149725797.USD","LU0320765489.SGD","LU0320765992.SGD","LU0942090050.USD","LU0787776722.HKD","LU1267930573.SGD","LU1791807156.HKD","LU0256863811.USD","LU1267930227.SGD","ASND","LU1814569148.SGD","BK4504","LU0310799852.SGD","IE0002270589.USD","LU0417517546.SGD","LU2361044949.HKD","BK4559","LU0683600562.USD","LU0648001328.SGD","LU1069347547.HKD","LU2461242641.AUD","LU0154236417.USD","LU0128525689.USD","LU0310800965.SGD","LU0070302665.USD","LU0128525929.USD","LU0477156953.USD","LU1506573853.SGD","LU0868494708.USD","LU1363072403.SGD","LU0251142724.SGD","LU1035773651.USD","BK4139","LU0106831901.USD","LU0130517989.USD","BK4207"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascendispharma.com","stockEarnings":[{"period":"1week","weight":0.0189},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.2791},{"period":"1year","weight":0.6517},{"period":"ytd","weight":0.0191}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0141},{"period":"3month","weight":0.045},{"period":"6month","weight":0.1},{"period":"1year","weight":0.1858},{"period":"ytd","weight":0.0124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.027537},{"month":2,"riseRate":0.545455,"avgChangeRate":0.052339},{"month":3,"riseRate":0.454545,"avgChangeRate":0.035071},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.034117},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.003499},{"month":6,"riseRate":0.636364,"avgChangeRate":0.020914},{"month":7,"riseRate":0.636364,"avgChangeRate":0.000335},{"month":8,"riseRate":0.727273,"avgChangeRate":0.084941},{"month":9,"riseRate":0.636364,"avgChangeRate":0.039794},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.00981},{"month":11,"riseRate":0.818182,"avgChangeRate":0.047363},{"month":12,"riseRate":0.545455,"avgChangeRate":0.041981}],"exchange":"NASDAQ","name":"Ascendis Pharma A/S","nameEN":"Ascendis Pharma A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Ascendis Pharma A/S(ASND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Ascendis Pharma A/S,ASND,Ascendis Pharma A/S股票,Ascendis Pharma A/S股票老虎,Ascendis Pharma A/S股票老虎国际,Ascendis Pharma A/S行情,Ascendis Pharma A/S股票行情,Ascendis Pharma A/S股价,Ascendis Pharma A/S股市,Ascendis Pharma A/S股票价格,Ascendis Pharma A/S股票交易,Ascendis Pharma A/S股票购买,Ascendis Pharma A/S股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Ascendis Pharma A/S(ASND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction